scPharmaceuticals' (SCPH) "Buy" Rating Reiterated at HC Wainwright

scPharmaceuticals (NASDAQ:SCPH - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They presently have a $18.00 target price on the stock. HC Wainwright's price objective suggests a potential upside of 475.08% from the stock's current price.

scPharmaceuticals Stock Up 4.3 %

Shares of SCPH traded up $0.13 during trading hours on Thursday, reaching $3.13. The company's stock had a trading volume of 485,705 shares, compared to its average volume of 325,961. The company has a 50 day moving average of $3.27 and a two-hundred day moving average of $3.75. The company has a quick ratio of 6.89, a current ratio of 8.08 and a debt-to-equity ratio of 1.66. The firm has a market cap of $157.39 million, a price-to-earnings ratio of -1.65 and a beta of 0.40. scPharmaceuticals has a 1-year low of $2.75 and a 1-year high of $5.65.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last announced its quarterly earnings data on Wednesday, March 19th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.05. scPharmaceuticals had a negative net margin of 264.60% and a negative return on equity of 244.93%. The firm had revenue of $12.15 million for the quarter, compared to the consensus estimate of $12.08 million. As a group, research analysts predict that scPharmaceuticals will post -1.53 EPS for the current fiscal year.

Remove Ads

Institutional Trading of scPharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of SCPH. Rubric Capital Management LP increased its position in scPharmaceuticals by 35.5% in the 3rd quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company's stock worth $21,774,000 after purchasing an additional 1,250,000 shares during the last quarter. AIGH Capital Management LLC grew its stake in shares of scPharmaceuticals by 1.2% in the 4th quarter. AIGH Capital Management LLC now owns 4,174,367 shares of the company's stock valued at $14,777,000 after buying an additional 50,000 shares in the last quarter. King Luther Capital Management Corp grew its stake in shares of scPharmaceuticals by 28.4% in the 4th quarter. King Luther Capital Management Corp now owns 2,857,910 shares of the company's stock valued at $10,117,000 after buying an additional 632,120 shares in the last quarter. Suvretta Capital Management LLC acquired a new position in scPharmaceuticals in the third quarter worth approximately $9,343,000. Finally, Thrivent Financial for Lutherans raised its position in scPharmaceuticals by 1.4% during the third quarter. Thrivent Financial for Lutherans now owns 1,048,938 shares of the company's stock valued at $4,783,000 after acquiring an additional 14,866 shares in the last quarter. 89.52% of the stock is currently owned by hedge funds and other institutional investors.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.